Skip to content

Evaluation of Ocular Surface Tumors Using Anterior Segment Optical Coherence Tomography (OCT)

Evaluation of Ocular Surface Tumors Using Anterior Segment Optical Coherence Tomography (OCT)

Status
Not yet recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06808126
Enrollment
58
Registered
2025-02-05
Start date
2025-03-01
Completion date
2026-05-01
Last updated
2025-02-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ocular Surface Tumors

Keywords

Optical Coherence Tomography

Brief summary

optical coherence tomography (OCT) can scan a range of ocular tissues and take high-resolution image sections during ophthalmic examination.. and recommended as a rapid, informative and quite reliable method of examination to differentiate benign from malignant ocular surface tumors. The conjunctiva is an anatomical site with a prominent risk of squamous cell carcinoma development, which is a unique biological behavior. The superficial lesion with significant epithelial cell growth usually displays unique data, contributing to unusual ocular tumors. Anterior segment optical coherence tomography (AS-OCT), as a noninvasive, high-resolution imaging technique, provides crucial morphological and anatomical information in ocular surface tumors via visualizing the layer structure of the cornea and anterior segment, qualifying tumor morphology, and quantifying thickness and extension. AS-OCT can provide valuable information for helping in clinical diagnoses, differential diagnoses, prognoses, and evaluating responses to treatments as a significant imaging tool in ocular surface tumors. The correct diagnosis and classification of ocular surface tumors are crucial aspects of their proper management. the aim of the study • To evaluate the imaging characteristics of ocular surface tumors on high-resolution anterior segment optical coherence tomography (ASOCT).

Detailed description

optical coherence tomography (OCT) can scan a range of ocular tissues and take high-resolution image sections during ophthalmic examination.. and recommended as a rapid, informative and quite reliable method of examination to differentiate benign from malignant ocular surface tumors. The conjunctiva is an anatomical site with a prominent risk of squamous cell carcinoma development, which is a unique biological behavior. The superficial lesion with significant epithelial cell growth usually displays unique data, contributing to unusual ocular tumors. Anterior segment optical coherence tomography (AS-OCT), as a noninvasive, high-resolution imaging technique, provides crucial morphological and anatomical information in ocular surface tumors via visualizing the layer structure of the cornea and anterior segment, qualifying tumor morphology, and quantifying thickness and extension. AS-OCT can provide valuable information for helping in clinical diagnoses, differential diagnoses, prognoses, and evaluating responses to treatments as a significant imaging tool in ocular surface tumors. The correct diagnosis and classification of ocular surface tumors are crucial aspects of their proper management. the aim of the study • To evaluate the imaging characteristics of ocular surface tumors on high-resolution anterior segment optical coherence tomography (ASOCT).

Interventions

None listed

Sponsors

Assiut University
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* all patients presented with ocular surface lesion suspected to be neoplastic

Exclusion criteria

* all patients presented with ocular surface lesion proved by pathology not to be neoplastic

Design outcomes

Primary

MeasureTime frameDescription
the accuracy of octbaselinethe accuracy of oct in diagnosis of Ocular Surface Tumors

Contacts

Primary ContactAmira Mohamed Abdelrahman Gebaly, residant doctor
amira.moh1998@gmail.com+201070445825

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026